diagnost tool
quest deliv strong start year
get better buy pt
quest deliv solid top bottom line beat driven much stronger volum
growth street expect quest good start add new
volum growth relat million new live recent health plan win unit
anthem horizon georgia quest expect volum gradual grow throughout
year reiter buy rate rais pt use
reason multipl revis adj ep estim
beat driven surprisingli strong volum adj ep beat
street rev y/i beat
volum grew ahead well street
despit fewer day headwind organ volum grew
help new health plan access acceler throughout
expect increas throughout ad point volum growth
point estim revenue /req decreas better
pama result impact
select one prefer lab unit unitedhealthcar
rate announc select quest ameripath/dermpath subsidiari
labcorp lh biorefer lab genedx invita mayo
clinic lab join newli creat prefer lab network pln launch juli
pln seek steer member get lowest cost test best
qualiti ie reduc wait time servic on-line schedul lab
measur quarterli perform indic unclear impact
part pln might indic price w/ remain
work in-network lab think sinc oper
prefer lab network think addit volum come name
better care servic lower price
reiter guid beat street estim reiter revenue
guid y/i adj ep guid greater assum
volum increas throughout year complet addit
expect see upsid least low end guid
model rais revenue estim rais
rev rais adj ep
respect estim exclud announc
yet could add anoth point growth
item in-network statu extend commerci cover
live us indic expect volum growth build year primarili
new live target opportun time build
revenu pharma custom newer clinic trial connect program
expect lower cost structur offset expect
reimburs impact see opportun reduc test denial
opportun acceler digit opportun consolid
immuno-assay provid opportun year
price close busi april
largest clinic lab us
focus routin gene-bas esoter test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
reiter buy rate rais pt use
multipl revis adj ep estim
believ potenti faster top-lin growth accret capit
deploy would mark upsid ep estim
acquisit deal stay call quest manag
indic remain activ involv sever health system evalu
hospit outreach strategi revenu guid continu assum point
growth includ point alreadi announc
seem grow awar low base financi
impact pama hospit outreach lab expect ramp
consolid lab ad point growth
vs growth sum acquisit cost
tailwind quest despit record year pama-pain sever help
tailwind quest busi year beyond first expect benefit
expand health plan access live anthem horizon georgia
quest size increment billion revenu opportun second
quest expect continu grow revenue growth/year
alreadi growth account deal announc last year
invigor cost save
possibl expans respons question call quest
manag remain activ involv larg hospit oper quest
help lower lab spend colorado believ expans
quest work across unit state would mark materi posit
catalyst price stock view
push retail quest expect expand footprint expand access directli
consum end locat safeway store
quest indic call expand footprint store
beyond state tx fl wal-mart store see path
quest direct aim make easier patient get test want similar
initi awar privately-held binx health quest live
quest direct provid individu abil log-on quest order
one test without consult physician individu
schedul time come patient servic center psc simpli come
without appoint provid sampl test manag indic
offer alreadi well receiv particularli among millenni
though clarifi age quest call demand std test includ ct/
ng syphili total std panel expand std panel
includ std test hcv hbv test addit test includ cbc
panel cholesterol drug screen panel gluten intoler panel
chang long-term target look drive revenu growth compound-annual-growth-rate
earn growth exclud benefit share
buyback remind quest novemb lower four-year earn
growth target compound-annual-growth-rate mid-to-high-singl digit cite headwind
reimburs pama carryov test
headwind hcvg vit wage inflat highlight challeng year
ahead view
pama note quit variabl outstand rate come
next pama period would take effect manag
indic expect relief particularli sinc lab book-of-busi
compress result expect clf cut expect year next
thu relief dollar basi unclear applic lab
gener data cut
cover compani also mention report
laboratori corpor america hold lh nyse hold
buy unchang target price april
diagnost tool
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price april
diagnost tool
canaccord genuiti estim compani report
buy unchang target price april
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin april et
date time product april et
pt use multipl revis adj ep estim believ potenti faster volum growth
market share gain top-lin growth accret capit deploy would mark upsid out-year ep
laboratori corpor america hold lh
price target lh appli multipl adj ep
risk achiev target price valuat
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
buy unchang target price april
diagnost tool
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
